September 11, 2019 – The annual exhibition on medical devices was exhibited in Bangkok, Thailand for 3 consecutive days. The 9th International Exhibition on Hospital, Diagnostic, Pharmaceutical, Medical & Rehabilitation Equipment & Supplies was conducted by the officials to bridge the demand and supply from stakeholders like manufacturers, distributors, and health service institutes. Universally acknowledged as an international event, some players around South East Asia were met and together establish new prospective collaboration to fill the gap in the SEA market of medical devices and services through export-import trading businesses. Proline joined with ASPAKI (Asosiasi Produsen Alat Kesehatan Indonesia – Indonesian Association of Medical Device Manufacturers) was introducing a diverse array of In Vitro Diagnostic products ranging from clinical chemistry analyzers, reagents, controls, calibrators, supplementaries, and immunoturbidimetric tests.
On September 12, 2019, Proline, represented by the Director of Prodia Diagnostic Line, Dr. Cristina Sandjaja, contributed to a technical presentation session talking about the latest monitoring evaluation on diabetic patients using Proline HbA1c net FS. The key topic was focused on the HbA1c new enzymatic test feature which delivers a better accurate and sensitive result on monitoring the patient’s critical condition compared to the older HbA1c test on the market.
Summarizing the expo, up to 11 countries coming from prospective distributors visited Proline’s booth. Most of the visitors were interested in knowing that Proline has already manufactured clinical chemistry reagents in Indonesia and partnered with DiaSys Germany as its primary material supplier for more than 8 years.